We demonstrated that when used at a pH where GPR65 is active, a GPR65-specific chemical probe can reduce the inflammatory signals that are produced by BMDCs, notably TNF and IL-12/23, which represent two key cytokines that are implicated in IBD and targeted by biologic therapies (51–53). Here, GPR65 is linked to inflammatory bowel disease.